Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases.

Reversing inflammatory lung disease remains the foremost challenge in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease. Reducing (or modifying) the underlying inflammatory process with mono-target drugs has proven challenging. The era of designing 'one target for one disease' has evolved such that a growing body of evidence suggests a single drug that is capable of specifically targeting multiple targets and pathways would be better at arresting progression of these respiratory diseases and be an important advancement in current therapy. Oligonucleotide-based drugs represent an emerging class of drug candidates. Their properties, a broader range of targets over conventional small-molecule drugs and recent clinical proof-of-concept support their development as novel multi-targeting agents for the treatment of respiratory diseases.

[1]  S. Quirce,et al.  Emerging drugs for asthma , 2012, Expert opinion on emerging drugs.

[2]  M. Sears.  Safe use of long-acting β-agonists: what have we learnt? , 2011, Expert opinion on drug safety.

[3]  N. Svrzikapa,et al.  Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Richard Graham Knowles,et al.  In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor , 2011, Journal of Pharmacology and Experimental Therapeutics.

[5]  Y. Brewah,et al.  IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. , 2011, American journal of respiratory and critical care medicine.

[6]  René Bernards,et al.  Taming the dragon: genomic biomarkers to individualize the treatment of cancer , 2011, Nature Medicine.

[7]  A. Anzueto,et al.  Optimizing management of chronic obstructive pulmonary disease in the upcoming decade , 2011, International journal of chronic obstructive pulmonary disease.

[8]  N. Ferrari,et al.  Oligonucleotides: New therapeutic approaches for asthma and chronic obstructive pulmonary disease. , 2010, Current opinion in investigational drugs.

[9]  P. Renzi,et al.  A multitargeted antisense therapy directed at CCR3 and the common β-chain of IL-3/IL-5/GM-CSF , 2010 .

[10]  R. Becker,et al.  First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention , 2010, Circulation.

[11]  S. Field,et al.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD , 2010, Drug design, development and therapy.

[12]  P. Barnes.  New therapies for asthma: is there any progress? , 2010, Trends in pharmacological sciences.

[13]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[14]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[15]  S. Holgate,et al.  Rethinking the pathogenesis of asthma. , 2009, Immunity.

[16]  P. Barnes,et al.  The cytokine network in chronic obstructive pulmonary disease. , 2009, American journal of respiratory cell and molecular biology.

[17]  P. Renzi,et al.  A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice , 2009, Respiratory research.

[18]  J. Fahy,et al.  Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. , 2009, Proceedings of the American Thoracic Society.

[19]  C. Vogelmeier,et al.  Emerging drugs in chronic obstructive pulmonary disease , 2009, Expert opinion on emerging drugs.

[20]  D. Broide,et al.  Advances in mechanisms of asthma, allergy, and immunology in 2008. , 2009, The Journal of allergy and clinical immunology.

[21]  A. Guimond,et al.  Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. , 2008, Pulmonary pharmacology & therapeutics.

[22]  B. Medoff,et al.  Allergic asthma: a tale of many T cells , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[23]  P. Barnes,et al.  The cytokine network in asthma and chronic obstructive pulmonary disease. , 2008, The Journal of clinical investigation.

[24]  S. Wenzel,et al.  The response to combination therapy treatment regimens in severe/difficult-to-treat asthma , 2008, European Respiratory Journal.

[25]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[26]  K. Larsson.  Inflammatory markers in COPD , 2008, The clinical respiratory journal.

[27]  R. Juliano,et al.  Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides , 2008, Nucleic acids research.

[28]  S. Steinhubl,et al.  Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease , 2008, Circulation.

[29]  L. Boulet,et al.  Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. , 2008, American journal of respiratory and critical care medicine.

[30]  B. Medoff,et al.  T cell trafficking in allergic asthma: the ins and outs. , 2008, Annual review of immunology.

[31]  S. Holgate,et al.  Treatment strategies for allergy and asthma , 2008, Nature Reviews Immunology.

[32]  P. J. Barnes,et al.  Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.

[33]  S. Agrawal,et al.  Synthetic agonists of Toll-like receptors 7, 8 and 9. , 2007, Biochemical Society transactions.

[34]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[35]  P. O'Byrne.  The demise of anti IL-5 for asthma, or not. , 2007, American journal of respiratory and critical care medicine.

[36]  J. Lötvall,et al.  Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD , 2007, Respiratory research.

[37]  P. Sly,et al.  Th2 cytokines in the asthma late-phase response , 2007, The Lancet.

[38]  S. Wenzel,et al.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.

[39]  M. Cairns,et al.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. , 2007, The American journal of pathology.

[40]  S. Steinhubl,et al.  First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity , 2006, Circulation.

[41]  R. Plasterk,et al.  The diverse functions of microRNAs in animal development and disease. , 2006, Developmental cell.

[42]  J. Hamilton,et al.  Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). , 2006, Pharmacology & therapeutics.

[43]  M. Damha,et al.  Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity. , 2006, Annals of the New York Academy of Sciences.

[44]  P. Renzi,et al.  Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats. , 2006, Oligonucleotides.

[45]  S. Wenzel.  Asthma: defining of the persistent adult phenotypes , 2006, The Lancet.

[46]  C. Page,et al.  The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]is , 2006, Journal of Pharmacology and Experimental Therapeutics.

[47]  Andrew D Ellington,et al.  Aptamer therapeutics advance. , 2006, Current opinion in chemical biology.

[48]  R. Djukanović,et al.  Inflammatory cells in the airways in COPD , 2006, Thorax.

[49]  N. Caplen,et al.  Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo , 2006, Respiratory research.

[50]  Florin-Dan Popescu.  Antisense‐ and RNA interference‐based therapeutic strategies in allergy , 2005, Journal of cellular and molecular medicine.

[51]  Richard W. Carthew,et al.  Silence from within: Endogenous siRNAs and miRNAs , 2005, Cell.

[52]  E. Ng,et al.  Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[53]  M. Schwarz,et al.  Multi-faceted strategies to combat disease by interference with the chemokine system. , 2005, Trends in immunology.

[54]  H. H. Choo,et al.  Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. , 2005, American journal of respiratory and critical care medicine.

[55]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[56]  E. Wouters,et al.  Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. , 2004, Chest.

[57]  P. Barnes.  Mediators of Chronic Obstructive Pulmonary Disease , 2004, Pharmacological Reviews.

[58]  A. Nicholson,et al.  Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes , 2004, Molecular Pharmacology.

[59]  George Quick,et al.  Antidote-mediated control of an anticoagulant aptamer in vivo , 2004, Nature Biotechnology.

[60]  Alexey Bochkarev,et al.  2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. , 2004, Nucleic acids research.

[61]  Patty J. Lee,et al.  Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia-Reperfusion-induced Lung Apoptosis* , 2004, Journal of Biological Chemistry.

[62]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[63]  P. Payette,et al.  Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities , 2004, European journal of immunology.

[64]  A. M. Houghton,et al.  Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. , 2003, The American journal of pathology.

[65]  R. E. Wiley,et al.  GM-CSF and dendritic cells in allergic airway inflammation: basic mechanisms and prospects for therapeutic intervention. , 2003, Current drug targets. Inflammation and allergy.

[66]  C. Bachert,et al.  Interleukin-5, eosinophilic diseases and therapeutic intervention. , 2003, Current drug targets. Inflammation and allergy.

[67]  M. Amarzguioui,et al.  Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. , 2003, Nucleic acids research.

[68]  L. Kunz-Schughart,et al.  Expression and Release of Interleukin-8 by Human Bronchial Epithelial Cells from Patients with Chronic Obstructive Pulmonary Disease, Smokers, and Never-Smokers , 2003, Respiration.

[69]  Jens Kurreck,et al.  Antisense technologies. Improvement through novel chemical modifications. , 2003, European journal of biochemistry.

[70]  P. Barnes,et al.  Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[71]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[72]  I. Pavord,et al.  TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. , 2002, The Journal of allergy and clinical immunology.

[73]  Jin Dai,et al.  Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. , 2002, American journal of respiratory and critical care medicine.

[74]  K. Izuhara,et al.  IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. , 2002, Current drug targets. Inflammation and allergy.

[75]  P. Barnes,et al.  Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD , 2002, Thorax.

[76]  F. Leenders,et al.  GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation. , 2002, Antisense & nucleic acid drug development.

[77]  R. Egan,et al.  Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. , 2001, American journal of respiratory cell and molecular biology.

[78]  S. Crooke.  Antisense Drug Technology , 2001 .

[79]  J. McGinty,et al.  Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. , 2001, American journal of respiratory and critical care medicine.

[80]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[81]  A. Levin,et al.  Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. , 2000, Antisense and Nucleic Acid Drug Development.

[82]  T. Hökfelt,et al.  Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[83]  S. Stafford,et al.  Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. , 2000, Blood.

[84]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[85]  M. Humbert,et al.  Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. , 1999, Journal of immunology.

[86]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[87]  Y. Cho‐Chung,et al.  Oligonucleotides as transcription factor decoys. , 1999, Current opinion in molecular therapeutics.

[88]  M. Cairns,et al.  Target site selection for an RNA-cleaving catalytic DNA , 1999, Nature Biotechnology.

[89]  R. Pauwels,et al.  The cellular composition of induced sputum in chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[90]  L. Miraglia,et al.  Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression* , 1999, The Journal of Biological Chemistry.

[91]  M. van de Rijn,et al.  Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. , 1998, American journal of respiratory cell and molecular biology.

[92]  L. Fabbri,et al.  Severity of airflow limitation is associated with severity of airway inflammation in smokers. , 1998, American journal of respiratory and critical care medicine.

[93]  S. Crooke.  Vitravene--another piece in the mosaic. , 1998, Antisense & nucleic acid drug development.

[94]  B. Balbi,et al.  Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. , 1998, The European respiratory journal.

[95]  J. Renauld,et al.  Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. , 1998, Journal of immunology.

[96]  A. Macleod,et al.  Identification and Partial Purification of Human Double Strand RNase Activity , 1998, The Journal of Biological Chemistry.

[97]  G. F. Joyce,et al.  A general purpose RNA-cleaving DNA enzyme. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[98]  W. Kuschner,et al.  Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. , 1996, The European respiratory journal.

[99]  V. Erdmann,et al.  Mirror-image RNA that binds D-adenosine , 1996, Nature Biotechnology.

[100]  P. Barnes,et al.  Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. , 1996, American journal of respiratory and critical care medicine.

[101]  J. Szostak,et al.  Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures , 1992, Nature.

[102]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[103]  P. Hausen,et al.  Enzyme from Calf Thymus Degrading the RNA Moiety of DNA-RNA Hybrids: Effect on DNA-Dependent RNA Polymerase , 1969, Science.

[104]  F. Finkelman,et al.  Key advances in mechanisms of asthma, allergy, and immunology in 2009. , 2010, The Journal of allergy and clinical immunology.

[105]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[106]  J. Monteseirín.  Neutrophils and asthma. , 2009, Journal of investigational allergology & clinical immunology.

[107]  Giorgio Valabrega,et al.  Multitarget drugs: the present and the future of cancer therapy. , 2009, Expert opinion on pharmacotherapy.

[108]  A. Nadeem,et al.  Adenosine receptors and asthma. , 2009, Handbook of experimental pharmacology.

[109]  P. Barnes.  Corticosteroid resistance in airway disease. , 2004, Proceedings of the American Thoracic Society.

[110]  Lei Tang,et al.  Clinical Potential of Respirable Antisense Oligonucleotides (RASONs) in Asthma , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[111]  A. Zlotnik,et al.  The biology of chemokines and their receptors. , 2000, Annual review of immunology.

[112]  S. Holgate.  Asthma: a dynamic disease of inflammation and repair. , 1997, Ciba Foundation symposium.

[113]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.